Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Inflammation Research
Erschienen in: Inflammation Research 7/2010

01.07.2010 | Original Research Paper

Vascular endothelial growth factor expression levels of gingiva in gingivitis and periodontitis patients with/without diabetes mellitus

verfasst von: Gonca Cayir Keles, Burcu Ozkan Cetinkaya, Cafer Eroglu, S. Burcak Simsek, Hakki Kahraman

Erschienen in: Inflammation Research | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective and design

The aim of this study was to determine vascular endothelial growth factor (VEGF) mRNA expression levels in gingival tissues of gingivitis and periodontitis patients with diabetes mellitus and those without. The hypothesis tested is that expression of VEGF, considered the effective cytokine in the relationship between diabetes and periodontal disease, is differentially affected in gingivitis and periodontitis patients with or without diabetes mellitus compared to healthy controls.

Methods

Forty-five subjects were evaluated in five groups; individuals with gingivitis (group 1; n = 10), individuals with periodontitis (group 2; n = 10), individuals with gingivitis + type II diabetes (group 3; n = 10), individuals with periodontitis + type II diabetes (group 4; n = 10), and individuals without periodontal and systemic disease (group 5; n = 5). VEGF mRNA levels in gingival tissues were measured by quantitative real-time PCR using Lightcycler.

Results

Expression of VEGF mRNA was detected in all groups. There was no significant difference in expression levels of VEGF mRNA between groups (P > 0.05).

Conclusions

VEGF expression is probably related to both maintenance of periodontal health and periodontal tissue destruction. It can be concluded that systemic condition in type II diabetes mellitus under good metabolic control does not seem to have additional effects on gingival tissue VEGF mRNA levels in gingivitis and periodontitis patients.
Literatur
1.
Booth V, Young S, Cruchley A, Taichman NS, Paleolog E. Vascular endothelial growth factor in human periodontal disease. J Periodontal Res. 1998;33:491–9.PubMed
2.
Honda T, Domon H, Okui T, Kajita K, Amanuma R, Yamazaki K. Balance of inflammatory response in stable gingivitis and progressive periodontitis lesions. Clin Exp Immunol. 2006;144:35–40.CrossRefPubMed
3.
Rodríguez-Martínez M, Patiño-Marín N, Loyola-Rodríguez JP, Brito-Orta MD. Gingivitis and periodontitis as antagonistic modulators of gingival perfusion. J Periodontol. 2006;77:1643–50.CrossRefPubMed
4.
Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13:18–32.PubMed
5.
6.
Johnson RB, Serio FG, Dai X. Vascular endothelial growth factors and progression of periodontal diseases. J Periodontol. 1999;70:848–52.CrossRefPubMed
7.
Suthin K, Matsushita K, Machigashira M, et al. Enhanced expression of vascular endothelial growth factor by periodontal pathogens in gingival fibroblasts. J Periodontal Res. 2003;38:90–6.CrossRefPubMed
8.
Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–39.PubMed
9.
Connolly DT. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem. 1991;47:219–23.CrossRefPubMed
10.
Nakagawa K, Chen YX, Ishibashi H, Yonemitsu Y, Murata T, Hata Y, et al. Angiogenesis and its regulation: roles of vascular endothelial cell growth factor. Semin Thromb Hemost. 2000;26:61–6.CrossRefPubMed
11.
Sakuta T, Matsushita K, Yamaguchi N, Oyama T, Motani R, Koga T, et al. Enhanced production of vascular endothelial growth factor by human monocytic cells stimulated with endotoxin through transcription factor SP-1. J Med Microbiol. 2001;50:233–7.PubMed
12.
Unlu F, Guneri PG, Hekimgil M, Yesilbek B, Boyacioglu H. Expression of vascular endothelial growth factor in human periodontal tissues: comparison of healthy and diabetic patients. J Periodontol. 2003;74:181–7.CrossRefPubMed
13.
Cetinkaya BO, Keles GC, Ayas B, Sakallioglu EE, Acikgoz G. The expression of vascular endothelial growth factor in a rat model at destruction and healing stages of periodontal disease. J Periodontol. 2007;78:1129–35.CrossRefPubMed
14.
Prapulla DV, Sujatha PB, Pradeep AR. Gingival crevicular fluid VEGF levels in periodontal health and disease. J Periodontol. 2007;78:1783–7.CrossRefPubMed
15.
Oyama T, Sakuta T, Matsushita K, Maruyama I, Nagaoka S, Torii M. Effects of roxithromycin on tumor necrosis factor-alpha-induced vascular endothelial growth factor expression in human periodontal ligament cells in culture. J Periodontol. 2000;71:1546–53.CrossRefPubMed
16.
Chapple CC, Kumar RK, Hunter N. Vascular remodelling in chronic inflammatory periodontal disease. J Oral Pathol Med. 2000;29:500–6.CrossRefPubMed
17.
Cohen DW, Friedman LA, Shapiro J, Kyle GC, Franklin S. Diabetes mellitus and periodontal disease: two-year longitudinal observations, I. J Periodontol. 1970;41:709–12.PubMed
18.
Rylander H, Ramberg P, Blohme G, Lindhe J. Prevalence of periodontal disease in young diabetics. J Clin Periodontol. 1987;14:38–43.CrossRefPubMed
19.
de Pommereau V, Dargent-Paré C, Robert JJ, Brion M. Periodontal status in insulin-dependent diabetic adolescents. J Clin Periodontol. 1992;19:628–32.CrossRefPubMed
20.
Grossi SG. Treatment of periodontal disease and control of diabetes: an assessment of the evidence and need for future research. Ann Periodontol. 2001;6:138–45.CrossRefPubMed
21.
Papapanou PN. Periodontal diseases: epidemiology. Ann Periodontol. 1996;1:1–36.PubMed
22.
Loe H. Periodontal disease: the sixth complication of diabetes mellitus. Diabetes Care. 1993;16:329–34.PubMed
23.
Clark CM Jr, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med. 1995;332:1210–7.CrossRefPubMed
24.
Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: a two-way relationship. Ann Periodontol. 1998;3:51–61.PubMed
25.
Malamitsi-Puchner A, Sarandakou A, Tziotis J, Dafogianni C, Bartsocas CS. Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type 1 diabetes mellitus. Pediatr Res. 1998;44:873–5.CrossRefPubMed
26.
Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes. 1999;48:1899–906.CrossRefPubMed
27.
Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl. 2000;77:S113–9.CrossRefPubMed
28.
Hernandez C, Burgos R, Canton A, Garcia-Arumi J, Segura RM, Simo R. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study. Diabetes Care. 2001;24:516–21.CrossRefPubMed
29.
de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol. 2001;12:993–1000.PubMed
30.
Petrovic MG, Korosec P, Kosnik M, Osredkar J, Hawlina M, Peterlin B, et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis. 2008;14:1382–7.PubMed
31.
Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247:21–6.CrossRefPubMed
32.
Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev. 2003;23:117–45.CrossRefPubMed
33.
Di Marco GS, Alam A, Dol F, Corvol P, Gasc JM, Larger E. Angiogenesis and diabetes: different responses to pro-angiogenic factors in the chorioallantoic membrane assay. Mol Med. 2008;14:705–14.CrossRefPubMed
34.
Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res. 2001;49:554–60.CrossRefPubMed
35.
Boodhwani M, Sodha NR, Mieno S, Xu SH, Feng J, Ramlawi B, et al. Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial ischemia in diabetes. Circulation. 2007;116:I31–7.CrossRefPubMed
36.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–25.CrossRefPubMed
37.
Johnson RB, Serio FG. Leptin within healthy and diseased human gingiva. J Periodontol. 2001;72:1254–7.CrossRefPubMed
38.
Guneri P, Unlu F, Yesilbek B, Bayraktar F, Kokuludag A, Hekimgil M, et al. Vascular endothelial growth factor in gingival tissues and crevicular fluids of diabetic and healthy periodontal patients. J Periodontol. 2004;75:91–7.CrossRefPubMed
39.
Sakallioglu EE, Aliyev E, Lutfioglu M, Yavuz U, Acikgoz G. Vascular endothelial growth factor (VEGF) levels of gingiva and gingival crevicular fluid in diabetic and systemically healthy periodontitis patients. Clin Oral Investig. 2007;11:115–20.CrossRefPubMed
40.
Lundy FT, Shaw C, McKinnell J, Lamey PJ, Linden GJ. Calcitonin gene-related peptide in gingival crevicular fluid in periodontal health and disease. J Clin Periodontol. 1999;26:212–6.CrossRefPubMed
41.
Seguier S, Godeau G, Brousse N. Collagen fibers and inflammatory cells in healthy and diseased human gingival tissues: a comparative and quantitative study by immunohistochemistry and automated image analysis. J Periodontol. 2000;71:1079–85.CrossRefPubMed
42.
Bogren A, Teles R, Torresyap G, Haffajee AD, Socransky SS, Lindhe J, et al. A three-year prospective study of adult subjects with gingivitis, I: clinical periodontal parameters. J Clin Periodontol. 2007;34:1–6.CrossRefPubMed
43.
Zheng P, Chen H, Shi S, Jepsen S, Eberhard J. Periodontal parameters and platelet-activating factor levels in serum and gingival crevicular fluid in a Chinese population. J Clin Periodontol. 2006;33:797–802.CrossRefPubMed
44.
Keles GC, Cetinkaya BO, Simsek SB, Koprulu D, Kahraman H. The role of periodontal disease on acute phase proteins in patients with coronary heart disease and diabetes. Turk J Med Sci. 2007;37:39–44.
45.
Silness J, Loe H. Periodontal disease in pregnancy, II: correlation between oral hygiene and periodontal condition. Acta Odontol Scand. 1964;22:121–35.CrossRefPubMed
46.
Loe H, Silness J. Periodontal disease in pregnancy, I: prevalence and severity. Acta Odontol Scand. 1963;21:533–51.CrossRefPubMed
47.
Hirose M, Ishihara K, Saito A, Nakagawa T, Yamada S, Okuda K. Expression of cytokines and inducible nitric oxide synthase in inflamed gingival tissue. J Periodontol. 2001;72:590–7.CrossRefPubMed
48.
Stove J, Schoniger R, Huch K, Brenner R, Gunther KP, Puhl W, et al. Effects of dexamethasone on proteoglycan content and gene expression of IL-1beta-stimulated osteoarthrotic chondrocytes in vitro. Acta Orthop Scand. 2002;73:562–7.CrossRefPubMed
49.
Yamamoto T, Feng L, Mizuno T, Hirose S, Kawasaki K, Yaoita E, et al. Expression of mRNA for natriuretic peptide receptor subtypes in bovine kidney. Am J Physiol. 1994;267:F318–24.PubMed
50.
Tokoro Y, Yamamoto T, Hara K. IL-1 beta mRNA as the predominant inflammatory cytokine transcript: correlation with inflammatory cell infiltration into human gingiva. J Oral Pathol Med. 1996;25:225–31.CrossRefPubMed
51.
Aiba T, Akeno N, Kawane T, Okamoto H, Horiuchi N. Matrix metalloproteinases-1 and -8 and TIMP-1 mRNA levels in normal and diseased human gingivae. Eur J Oral Sci. 1996;104:562–9.CrossRefPubMed
52.
Oliver RC, Tervonen T. Diabetes: a risk factor for periodontitis in adults? J Periodontol. 1994;65:530–8.PubMed
53.
Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995;372:83–7.CrossRefPubMed
54.
Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219–24.CrossRefPubMed
55.
Tremolada G, Lattanzio R, Mazzolari G, Zerbini G. The therapeutic potential of VEGF inhibition in diabetic microvascular complications. Am J Cardiovasc Drugs. 2007;7:393–8.CrossRefPubMed
Metadaten
Titel
Vascular endothelial growth factor expression levels of gingiva in gingivitis and periodontitis patients with/without diabetes mellitus
verfasst von
Gonca Cayir Keles
Burcu Ozkan Cetinkaya
Cafer Eroglu
S. Burcak Simsek
Hakki Kahraman
Publikationsdatum
01.07.2010
Verlag
SP Birkhäuser Verlag Basel
Erschienen in
Inflammation Research / Ausgabe 7/2010
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-010-0158-8

Weitere Artikel der Ausgabe 7/2010

Inflammation Research 7/2010 Zur Ausgabe

Erratum

Erratum to: Abstract supplement to the 8th World Congress on Trauma, Shock, Inflammation and Sepsis – TSIS 2010

Original Research Paper

Over-expression of caveolin-1 aggravate LPS-induced inflammatory response in AT-1 cells via up-regulation of cPLA2/p38 MAPK

Original Research Paper

Hyaluronic acid inhibits nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes in vitro

Original Research Paper

Early administration of propofol protects against endotoxin-induced acute lung injury in rats by inhibiting the TGF-β1-Smad2 dependent pathway

Erratum

Erratum to: Early administration of propofol protects against endotoxin-induced acute lung injury in rats by inhibiting the TGF-β1-Smad2 dependent pathway

Original Research Paper

Effects of alpha 1-antitrypsin on endotoxin-induced lung inflammation in vivo

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

04.06.2024 Interventionelle Verfahren in der Kardiologie Nachrichten

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise